# Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

> **NCT05874401** · PHASE4 · RECRUITING · sponsor: **Pharmacosmos A/S** · enrollment: 302 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Placebo
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT05874401
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 302 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874401, "Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05874401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*